Paclitaxel in Metastatic Breast Cancer:-a Trial of Two Doses by a 3-Hour Infusion in Patients With Dith Disease Recurrence After Prior Therapy With Anthracyclines

Abstract

Paclitaxel by a 3-hour infusion in combination with doxorubicin should be investigated in patients with metastatic breast cancer. Unless randomized trials demonstrate greater efficacy of the more toxic higher dose, it is suggested that a dose of 175-200 mg/m2 be administered with the 3-hour infusion schedule.